Beyond Cytotoxic Chemotherapy for the First-Line Treatment of HER2-Negative, Hormone-Insensitive Metastatic Breast Cancer: Current Status and Future Opportunities
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference70 articles.
1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005
2. Trends in breast cancer by race and ethnicity: update 2006;Smigal;CA Cancer J Clin,2006
3. Single agent versus combination chemotherapy for metastatic breast cancer;Carrick;Cochrane Database Syst Rev,2005
4. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193);Sledge;J Clin Oncol,2003
5. Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: a prospective randomized trial;Joensuu;J Clin Oncol,1998
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cross-attention multi-branch CNN using DCE-MRI to classify breast cancer molecular subtypes;Frontiers in Oncology;2023-03-07
2. Discovery and Validation of a Novel Metastasis-Related lncRNA Prognostic Signature for Colorectal Cancer;Frontiers in Genetics;2022-05-19
3. Mindfulness for the Self-Management of Fatigue, Anxiety, and Depression in Women With Metastatic Breast Cancer;Integrative Cancer Therapies;2014-08-26
4. Living with Advanced Breast Cancer among Ghanaian Women: Emotional and Psychosocial Experiences;International Journal of Palliative Care;2014-06-25
5. Triple Negative Breast Cancer;Asian Pacific Journal of Cancer Prevention;2014-03-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3